Karen J. Wilson - 01 Jan 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Director
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Issuer symbol
LVTX
Transactions as of
01 Jan 2025
Net transactions value
$0
Form type
3
Filing time
02 Jan 2025, 09:35:12 UTC
Previous filing
25 Nov 2024
Next filing
15 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LVTX Common Shares 10,000 01 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 24,261 $15.00 Direct F1
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 20,000 $5.10 Direct F1
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 20,000 $3.64 Direct F1
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 33,390 $1.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and immediately exercisable.
F2 100% of the shares underlying the option vest on January 19, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date.